Launch a Health-System-Owned Oncology Specialty Pharmacy

1. 1

   Quantify the captured-margin and coordination case

   The reason a system builds its own specialty pharmacy is to stop giving away margin and care coordination to outside pharmacies for its own oncology patients. Quantify the specialty-drug volume currently leaving the system and the integrated-care benefit of keeping it in-house. This business case, built on existing captive volume, is what makes the health-system model distinct from a standalone independent.

2. 2

   Build the accredited pharmacy operation

   The system must obtain state licensure and specialty-pharmacy accreditation (URAC, ACHC) and build hazardous-drug handling, dispensing, and clinical programs to standard. Existing health-system pharmacy expertise helps, but specialty accreditation is its own bar. This is the regulatory gate before dispensing.

3. 3

   Secure limited-distribution drug access

   Even with captive patients, the system needs manufacturers to include it in limited-distribution networks for the oncology drugs its patients require, which is not automatic. Pursue these agreements early, because lack of access forces prescriptions back out to competitors. Scale and integrated clinical data can strengthen the case to manufacturers.

4. 4

   Win payer-network inclusion

   The pharmacy must contract with the payers and PBMs covering its patients, and some networks favor PBM-owned pharmacies, which can block access even to a system's own patients. Payer contracting is a real obstacle and sometimes the binding constraint. Address it in the business case honestly.

5. 5

   Integrate dispensing with the clinics

   The unique advantage is tight integration with the oncology clinics, EHR, and care team, enabling coordinated prior authorization, adherence, and side-effect management inside one record. Build the workflows that connect prescriber, pharmacist, and patient. This integrated loop is the clinical payoff and the retention driver.

6. 6

   Consider a 340B and financial strategy

   Many health systems participate in the 340B drug pricing program, which can materially affect specialty-pharmacy economics and must be managed within program rules. Model the financial strategy including 340B where applicable. Compliance with 340B and contract-pharmacy rules is essential and closely watched.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.